Our Mission
We are dedicated to addressing unmet medical needs in cardiovascular health by transforming and enhancing existing medications. Our mission is to improve patient outcomes by delivering Value-Added Medications in convenient dosage forms that benefit patients, healthcare providers, and payors alike.
Latest news
Chronic stable angina
most often occurs on the background of atherosclerotic coronary artery disease
Current angina treatments are either poorly suited or even contraindicated in patients with significant bradycardia or heart block, as many anti-anginal drugs, such as beta-blockers or non-dihydropyridine calcium channel blockers, may exacerbate these conditions.
1. Marinescu et al. JACC Cardiovasc Imaging. 2015;8(2)210-220. 2. Patel MR et al. N Engl J Med. 2010;362:886-95. 3. Bradly C, Berry C. J Nucl Cardiol. 2022;29;1763-75. 4. Taqueti VR, Di Carli MF. J Am Coll Cardiol. 2018;72(21):2625-2641. 5. Chen JW et al. Am J Cardiol. 1997;80;32-38. 6. Zhu H et al. Clin Ther. 2019;41(10)2137-2152. 7. Kaski JC et al. Circulation. 2018;138;1463-1480. 8.Knuuti, J et al. Eur Heart J. 2020;41,:407-477
Chronic stable angina
is a highly prevalent condition taking a heavy toll on millions of people
It is the symptomatic side of coronary artery disease (CAD), typically manifesting as chest pain and shortness of breath
Our solution - AUX-001 - effective angina symptom-controlling agent
with proven hospitalization reduction effect
Auxilius Pharma is actively working on introducing AUX-001 to key markets worldwide as a first-line medication, taken once daily, based on well-established, long-term efficacy and safety results of the active ingredient nicorandil.
